Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis
Open Access
- 16 November 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 44 (2), 145-150
- https://doi.org/10.1093/rheumatology/keh390
Abstract
Background. To determine the efficacy of calcium channel blockers (CCBs) for primary Raynaud's phenomenon (RP). Primary outcomes were frequency and severity of RP attacks.Keywords
This publication has 27 references indexed in Scilit:
- Comparison of Sustained-Release Nifedipine and Temperature Biofeedback for Treatment of Primary Raynaud PhenomenonArchives of Internal Medicine, 2000
- Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trialArthritis & Rheumatism, 1999
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Systematic Reviews: Identifying relevant studies for systematic reviewsBMJ, 1994
- Vibrotactile Sensation and Response to Nifedipine Dose Titration in Primary Raynaud's PhenomenonAngiology, 1989
- The Effect of the Calcium‐entry Blocker Nifedipine on Cold‐induced Digital VasospasmActa Medica Scandinavica, 1987
- Clinical and rheological effects of nifedipine in Raynaud's phenomenon.British Journal of Clinical Pharmacology, 1986
- Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenonAmerican Heart Journal, 1986
- A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenonEuropean Heart Journal, 1986
- Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's PhenomenonNew England Journal of Medicine, 1983